References
- Akimoto Y, Kobayashi H, Shinozaki Y, Urakubo G. (1986). Studies on metabolic fate of oxybutynin hydrochloride (4). Metabolism in rat. Iyakuhin Kenkyu 17:1070–7
- Canavesi R, Aprile S, Giovenzana GB, et al. (2016). New insights in oxybutynin chemical stability: Identification in transdermal patches of a new impurity arising from oxybutynin N-oxide rearrangement. Eur J Pharm Sci 84:123–31
- Douchamps J, Derenne F, Stockis A, et al. (1988). The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35:515–20
- Hughes KM, Lang JC, Lazare R, et al. (1992). Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 22:859–69
- Lindeke B, Hallström G, Johansson C, et al. (1981). Metabolism of Oxybutynin: establishment of desethyloxybutynin and oxybutynin N-oxide formation in rat liver preparation using deuterium substitution and gas chromatographic mass spectrometric analysis. Biomed Mass Spectrom 8:506–13
- Matucci R, Nesi M, Martino MV, et al. (2016). Carbachol dimers as homobivalent modulators of muscarinic receptors. Biochem Pharmacol 108:90–101
- Mizushima H, Kinoshita K, Abe K, et al. (2007). Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats. Biol Pharm Bull 30:955–62
- Sato Y, Miyashita A, Iwatsubo T, Usui T. (2012). Conclusive identification of the oxybutynin-hydrolyzing enzyme in human liver. Drug Metab Dispos 40:902–6
- Shaw GL, Pate HR. (2007). Transdermal oxybutynin: a review. Expert Opin Drug Metab Toxicol 3:435–9
- Shinozaki Y, Monden R, Manaka A, et al. (1986). Studies on metabolic fate of oxybutynin hydrochloride (3). Metabolism in human and dog and the site of biotransfornation and the effect on enzymes induction in the rats. Drug Metab Pharmacokinet 1:341–52
- Staskin DR, Salvatore S. (2010). Oxybutynin topical and transdermal formulations: an update. Drugs Today 46:417–25
- Yaïch M, Popon M, Medard Y, Aigrain EJ. (1998). In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics 8:449–51
- Szabó A, Hermecz I. (2001). Novel intramolecular rearrangement of tertiary propargylamine N-oxides. J Org Chem 66:7219–22
- Zobrist RH, Schmid B, Feick A, et al. (2001). Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 18:1029–3104